Compare · AXSM vs TXMD
AXSM vs TXMD
Side-by-side comparison of Axsome Therapeutics Inc. (AXSM) and TherapeuticsMD Inc. (TXMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXSM and TXMD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AXSM is the larger of the two at $12.68B, about 588.8x TXMD ($21.5M).
- Over the past year, AXSM is up 132.2% and TXMD is up 49.0% - AXSM leads by 83.2 points.
- AXSM has hit the wire 23 times in the past 4 weeks while TXMD has been quiet.
- AXSM has more recent analyst coverage (25 ratings vs 2 for TXMD).
- Company
- Axsome Therapeutics Inc.
- TherapeuticsMD Inc.
- Price
- $250.51+1.72%
- $1.89+3.01%
- Market cap
- $12.68B
- $21.5M
- 1M return
- +12.10%
- -8.05%
- 1Y return
- +132.21%
- +49.01%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 23
- 0
- Recent ratings
- 25
- 2
Axsome Therapeutics Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
TherapeuticsMD Inc.
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17Ã-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-007HR and TX-008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Latest AXSM
- Director Saad Mark E converted options into 1,429 shares, increasing direct ownership by 14% to 11,431 units (SEC Form 4)
- Director Jeffs Roger converted options into 1,429 shares, increasing direct ownership by 2% to 58,939 units (SEC Form 4)
- Director Mahony Susan converted options into 1,429 shares and sold $145,017 worth of shares (600 units at $241.69) as part of a pre-agreed trading plan (SEC Form 4)
- Director Coleman Mark converted options into 1,429 shares and sold $160,107 worth of shares (643 units at $249.00) as part of a pre-agreed trading plan, increasing direct ownership by 3% to 30,389 units (SEC Form 4)
- SEC Form 144 filed by Axsome Therapeutics Inc.
- SEC Form 144 filed by Axsome Therapeutics Inc.
- SEC Form 144 filed by Axsome Therapeutics Inc.
- Axsome Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Axsome Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 4 filed by Director Coleman Mark
Latest TXMD
- SEC Form 10-Q filed by TherapeuticsMD Inc.
- TherapeuticsMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- TherapeuticsMD Announces First Quarter 2026 Financial Results
- Amendment: SEC Form 10-K/A filed by TherapeuticsMD Inc.
- SEC Form NT 10-K filed by TherapeuticsMD Inc.
- TherapeuticsMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-K filed by TherapeuticsMD Inc.
- TherapeuticsMD Announces Full Year 2025 Financial Results
- Director Thompson Tommy G bought $14,031 worth of shares (8,400 units at $1.67), increasing direct ownership by 57% to 23,179 units (SEC Form 4)
- TherapeuticsMD Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders